Michael Leuchten
Stock Analyst at Jefferies
(0.33)
# 4,498
Out of 5,055 analysts
514
Total ratings
46.2%
Success rate
-4.3%
Average return
Main Sectors:
Stocks Rated by Michael Leuchten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: ROP Roche Holding AG | Reiterated: Sell | CHF 230.00 → CHF 250.00 | CHF 370.90 | -32.60% | 72 | Oct 12, 2026 | |
| EPA: SAN Sanofi | Reiterated: Buy | €100.00 | €71.82 | +39.24% | 24 | Oct 7, 2026 | |
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 17,500p | 12,300p | +42.28% | 108 | Oct 7, 2026 | |
| LON: GSK GSK plc | Reiterated: Buy | 2,500p | 1,816p | +37.67% | 49 | Sep 29, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Hold | CHF 110.00 | CHF 122.66 | -10.32% | 16 | Sep 7, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Reiterated: Hold | €46.00 | €45.07 | +2.06% | 96 | Aug 10, 2026 | |
| GSK GSK plc | Reiterated: Buy | $56 → $67 | $47.87 | +40.17% | 4 | May 29, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Reiterated: Buy | €470.00 | €258.00 | n/a | 42 | Aug 21, 2023 | |
| ETR: MRK Merck KGaA | Reiterated: Buy | €208.00 | €141.90 | n/a | 40 | Aug 4, 2023 | |
| EPA: IPN Ipsen S.A. | Reiterated: Hold | €108.00 → €113.00 | €145.60 | n/a | 11 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €420.00 → €390.00 | €216.40 | n/a | 10 | Jun 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 2,650p | 3,912p | n/a | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $38.12 | n/a | 20 | Jun 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | €400.00 | €205.50 | n/a | 6 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €83.00 → €80.00 | €38.33 | n/a | 4 | Nov 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €40.00 → €45.00 | €43.56 | n/a | 2 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 75.00 → CHF 85.00 | CHF 53.38 | n/a | 6 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $39.77 | n/a | 1 | May 12, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $146.88 | n/a | 2 | Apr 22, 2016 |
Roche Holding AG
Oct 12, 2026
Reiterated: Sell
Price Target: CHF 230.00 → CHF 250.00
Current: CHF 370.90
Upside: -32.60%
Sanofi
Oct 7, 2026
Reiterated: Buy
Price Target: €100.00
Current: €71.82
Upside: +39.24%
AstraZeneca PLC
Oct 7, 2026
Reiterated: Buy
Price Target: 17,500p
Current: 12,300p
Upside: +42.28%
GSK plc
Sep 29, 2026
Reiterated: Buy
Price Target: 2,500p
Current: 1,816p
Upside: +37.67%
Novartis AG
Sep 7, 2026
Reiterated: Hold
Price Target: CHF 110.00
Current: CHF 122.66
Upside: -10.32%
Bayer Aktiengesellschaft
Aug 10, 2026
Reiterated: Hold
Price Target: €46.00
Current: €45.07
Upside: +2.06%
GSK plc
May 29, 2026
Reiterated: Buy
Price Target: $56 → $67
Current: $47.87
Upside: +40.17%
Sartorius Aktiengesellschaft
Aug 21, 2023
Reiterated: Buy
Price Target: €470.00
Current: €258.00
Upside: n/a
Merck KGaA
Aug 4, 2023
Reiterated: Buy
Price Target: €208.00
Current: €141.90
Upside: n/a
Ipsen S.A.
Jun 30, 2023
Reiterated: Hold
Price Target: €108.00 → €113.00
Current: €145.60
Upside: n/a
Jun 19, 2023
Reiterated: Buy
Price Target: €420.00 → €390.00
Current: €216.40
Upside: n/a
Oct 10, 2022
Reiterated: Buy
Price Target: 2,650p
Current: 3,912p
Upside: n/a
Jun 28, 2022
Downgraded: Sell
Price Target: n/a
Current: $38.12
Upside: n/a
Feb 28, 2022
Reiterated: Sell
Price Target: €400.00
Current: €205.50
Upside: n/a
Nov 4, 2021
Reiterated: Buy
Price Target: €83.00 → €80.00
Current: €38.33
Upside: n/a
Nov 2, 2021
Reiterated: Hold
Price Target: €40.00 → €45.00
Current: €43.56
Upside: n/a
Aug 23, 2021
Reiterated: Buy
Price Target: CHF 75.00 → CHF 85.00
Current: CHF 53.38
Upside: n/a
May 12, 2016
Upgraded: Buy
Price Target: n/a
Current: $39.77
Upside: n/a
Apr 22, 2016
Upgraded: Hold
Price Target: n/a
Current: $146.88
Upside: n/a